Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.
Thomas Willemsen
Advertisement
Articles by Thomas Willemsen
Advertisement
Latest Updated Articles
Targeting Hematological Malignancies With Autologous and Allogeneic Cell TherapiesPublished: November 22nd 2022 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma
2
Crawford Strunk, MD, on Integrating Gene Therapy into Clinical Care for Sickle Cell Disease
3
Crawford Strunk, MD, on the Importance of Palliative Care in Sickle Cell Disease
4
The Importance of Palliative Care in Sickle Cell Disease
5
